IL6 and cancer: Thus, the mechanism by which Grp94-IgG complexes might activate the inflammatory, anti-tumor response in PBMCs of cancer patients would predict that activated macrophages secrete both IL-6 and TNFα that, besides mutually reinforcing their own secretion [50], affect B lymphocytes, causing both the inhibition of the IgG production and the reactive anti-inflammatory secretion of IL-10 (Figure 5).